- Home
- ANVS vs BCAB Comparison
ANVS vs BCAB Comparison
Compare ANVS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | BCAB |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 71.6M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANVS | BCAB |
|---|---|---|
| Price | $3.86 | $0.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $13.50 | $1.00 |
| AVG Volume (30 Days) | ★ 4.0M | 2.1M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.24 |
| 52 Week High | $6.37 | $1.62 |
Technical Indicators
Market Signals| Indicator | ANVS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 48.08 |
| Support Level | $4.12 | $0.79 |
| Resistance Level | $4.64 | $0.90 |
| Average True Range (ATR) | 0.53 | 0.13 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 18.03 | 18.80 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.